borderline hypertensive (low risk), a SBP of 160-179 mm Hg is considered hypertensive (moderate risk) and a SPB ≥ 180 mm Hg is considered severely hypertensive (severe risk). 6, 7 Hypertension in cats frequently is associated with an underlying disease, with chronic kidney disease (CKD) and hyperthyroidism most commonly reported. 2, 4, 8, 9 Idiopathic hypertension is estimated to occur in up to 20% of cases. 10, 11 The aim of identifying hypertension early is to decrease the risk of TOD. 6 Target organ damage can occur in the brain, 12 eyes, 13 heart, 12 or kidneys 6 with ocular TOD most easily recognized in association with hypertension in general practice. Target organ damage is associated with considerable morbidity, including blindness, ventricular hypertrophy, proteinuria, and hypertensive encephalopathy. 5, 13, 14 Amlodipine, a calcium channel blocker, is recommended for the treatment of hypertension 6, 7 and has been found to be effective at decreasing blood pressure in hypertensive cats. 8, 15, 16 Limited research has been done into survival after diagnosis of hypertension in cats that are presented to primary care practice (PCP) in the United Kingdom (UK). Median survival time previously has been estimated to be up to 490 days in cats that were not proteinuric at diagnosis, whereas median survival time has been estimated to be 162 days in cats that were proteinuric at diagnosis. 8 Urine protein:
creatinine ratio (UPC) has been found to be correlated with decreased survival when adjusted for IRIS stage, both when assessed at initial diagnosis and as the time-averaged UPC while on treatment. 8 Much of the published data however derive from a small number of practices and referral centers where specific screening as well as diagnostic and treatment protocols tend to be followed. Thus, there is a deficiency of information on hypertension that is diagnosed in cats presented to PCP in the UK and how these cats are managed by general practitioners. The use of data from electronic patient records (EPRs) allows epidemiological studies on a large dataset that can be generalized to the cat population presented to PCP in the UK. The aims of our study were to estimate the proportion of cats in the UK receiving blood pressure assessment (BPA), describe cats diagnosed with hypertension, and investigate survival after diagnosis of hypertension in cats presented to PCP in the UK. Sample size calculations indicated that 212 hypertensive cats would be required to detect an all-cause mortality hazard ratio (HR) of 0.5 for a variable to which 75% of cats were exposed (eg, amlodipine use) with a power of 80% and 95% confidence, assuming, on average, 365 days of follow-up. 19 
| MATERIALS AND METHODS

| Statistical Analysis
For the calculations of proportion of cats that received BPA and the incidence risk of hypertension, age was categorized as <9 years and ≥9 years or as <4.5 years, 4.5 to <9 years, 9 to <13.5 years, 13. by examining Cox-Snell residuals, and competing models were assessed using the Akaike information criterion and the Bayesian information criterion. Predictive ability of the model was assessed using Harrell's C statistic, and outliers were evaluated using deviance residuals. 23 Statistical significance was set at the 5% level.
3 | RESULTS
| Blood pressure assessment
Of the 347 889 cats that were presented to 244 PCPs from January Most cats (94.8%; 1370) were assessed using blood pressure measurement. Seventy (4.8%) cats were predicted to be normotensive or hypertensive by ocular examination alone and 5 (0.04%) on clinical signs alone. The proportion of cats having their blood pressure assessed increased with age. Presentation with clinical signs was the most common reason for a cat to have its blood pressure assessed (Table 1) . Owners of further 0.50% (95% CI, 0.46-0.53) or 535 cats were offered a blood pressure measurement during the study period but declined.
| Incidence of hypertension
Of the 1445 cats identified that had their blood pressure assessed during the study period (2 years), 282 cats were diagnosed as hypertensive during the study period. This resulted in an estimated incidence risk of 19.5% (95% CI, 17.5-21.6) over the study period.
Incidence increased with age and was higher in crossbred cats than in purebred cats. Hypertension was most frequently diagnosed in cats presented for evaluation of clinical signs ( Table 2 ).
| Descriptive statistics
All further analysis was undertaken on the 282 incident cases of 
| Survival Analysis
Thirty-five cats diagnosed with hypertension had no follow-up.
Twenty-seven cats had <7 days follow-up and 220 cats had ≥7 days follow-up.. Of the 35 cats with no follow-up, 82.9% (29) were euthanized at the time of diagnosis of hypertension, and the remaining 6 were not presented to the practice again after diagnosis. Of the 27 cats that had <7 days follow-up, 17 (63.0%) were euthanized, 1 (3.7%) died naturally and 9 (33.3%) were censored. The most common reasons for euthanasia were quality of life (QOL; 35.3%; n = 6), CKD (23.5%; n = 4) and blindness (11.8%; n = 2). All further analysis only includes those cats with ≥7 days follow-up. Just over a third (38.6%; n = 85) of the cats with ≥7 days follow-up were subsequently lost to follow-up and 130 (59.1%) died during the follow-up period The final multivariable model included retinal detachment, tortuous vessels, reason for presentation, investigations after diagnosis, amlodipine use, CKD diagnosis, and diabetes mellitus diagnosis (Table 4) . Cats not receiving amlodipine treatment were at increased hazard of death (HR, 1.59; 95% CI, 0.98-2.55; P = .06) compared to those that did receive it but had no dose change, although the difference was not significant at the 5% level in the multivariable analysis.
Cats that received amlodipine but required a dose change were at decreased hazard of death (HR, 0.56; 95% CI, 0.36-0.87; P = .01). Cats that had retinal detachment or tortuous vessels at diagnosis were at increased hazard of death, as were cats with a diagnosis of CKD or diabetes mellitus. Cats that were presented for monitoring of concurrent disease and cats that had investigations for underlying disease after diagnosis of hypertension were at decreased hazard of death.
There was no evidence of interaction in the model and the proportional hazard assumption was met. Predictive ability of the model and model fit was adequate (Harrell's C, 0.68).
| Blood pressure and treatment
Cats that received amlodipine treatment alone had significantly higher the results of our study suggest a benefit for cats that are screened for hypertension because they survived longer than those that had developed clinical signs of hypertension leading to their diagnosis.
Whether early treatment of hypertension in cats that are screened decreases morbidity and mortality related to hypertension cannot be determined by this retrospective study. However, prospective experimental studies suggest that by lowering blood pressure, amlodipine does protect against hypertensive ocular damage. 25 Cats with a diagnosis of CKD or hyperthyroidism or apparently healthy cats ≥9 years also are recommended to have regular blood pressure measurements because of increased risk of hypertension. 2, 6, 26 In our study population, just under 24% of cats were ≥9 years of age. Previous research has estimated that 3.6% of cats have a diagnosis of CKD and 3% of cats have a diagnosis of hyperthyroidism in the PCP-attending population. 27 This suggests that blood pressure measurement is not being utilized routinely as a screening measure in higher risk cats, based on the lower proportion of cats receiving BPA and having it recommended. This could be because of in a busy clinic because of the lack of confidence in the accuracy of the result. 10 Very few cats <9 years had their blood pressure assessed. Without a baseline blood pressure measurement, as discussed in the ACVIM guidelines, 6 it may be more difficult for veterinarians to assess if there has been an increase in blood pressure, potentially delaying the diagnosis of hypertension in some cats.
Calculated incidence risk was similar to that previously estimated from healthy cat populations, but previous studies were conducted on cats ≥9 years of age. [1] [2] [3] In our study, most cats that received BPA were ≥9 years, which may explain the similarities with previous studies. Blood pressure assessment appears to have been targeted at high risk cats in our study population (ie, older cats, cats with pre-existing disease, and cats with clinical signs). Subclinical disease may have been missed because few cats were diagnosed with hypertension before clinical signs were present. This may result in the incidence estimate calculated being an underestimate of the true incidence of hypertension.
Median blood pressure at diagnosis was within the severe risk ACVIM category, with most cats having blood pressure of ≥180 mm Hg at diagnosis. This finding is consistent with most cats showing clinical signs of TOD at diagnosis. Earlier diagnosis of hypertension may decrease the number of cats presenting with evidence of TOD, as has been seen in a study that enrolled cats with lower blood pressure at diagnosis of hypertension, 15 which may decrease the morbidity associated with the condition. In another study that performed regular blood pressure measurements longitudinally in initially normotensive cats, 52% were found to have evidence of TOD at the point at which they were diagnosed with hypertension, 2 lower than the proportion of cats with TOD at time of diagnosis in our study. Hypertension is considered to cause harm by resulting in TOD, and decreasing QOL in these cats. 6 Quality of life was found to be decreased in hypertensive cats before starting treatment in 1 study, 15 and QOL was the most frequently reported reason for euthanasia in our study. Some clinical signs associated with CKD have been found to negatively impact QOL of cats with CKD. 28 Neurological signs have been reported to be the 6th most common reason for death in cats attending PCP. 29 This observation would all suggest that clinical disease associated with TOD may decrease QOL in cats. Because all cats diagnosed with diabetes mellitus were euthanized, it is possible that the QOL impact on the cat and owner of this disease influenced the HR calculated in our study, and that the impact of hypertension on death in these cats is lower than calculated. Additionally, blood pressure at diagnosis was not associated with survival. However, an association was identified between TOD and survival, which suggests that severity of hypertension (as reflected by evidence of TOD rather than a single blood pressure measurement made in the clinic) is associated with survival after diagnosis.
Blood pressure monitoring of cats after diagnosis was limited, which may mean that control of blood pressure was inadequate in some cats and did not result in a decrease in blood pressure that would decrease the cat's risk of TOD. The UPC was measured in a minority of cats, despite the association between both UPC at diagnosis and the time averaged UPC after treatment and survival after hypertension diagnosis. 8 Primary care veterinarians may not be aware of this association, or owners may decline to have UPC measured.
The use of urine dipstick tests to assess cat urine for the presence of protein lacks sensitivity and specificity. 24 Cats requiring an increase in amlodipine dose were found to have significantly higher blood pressure at diagnosis in comparison to those that did not. This finding is in agreement with a recent study, 16 even though not all cats had a follow-up blood pressure measurement to ensure adequate blood pressure control in our study. Because of inadequate monitoring, it was not possible to investigate the association between blood pressure control and survival after hypertension diagnosis.
Retinal detachment and tortuous vessels identified at diagnosis of hypertension both were associated with increased hazard of death.
These cats also may have had TOD in other organs, such as the heart, that may have predisposed them to more life-limiting clinical signs.
The owners of these cats also may have chosen to euthanize them sooner than cats without these clinical signs because of their perceived decreased QOL. Hypertensive cats that were diagnosed while being monitored for hypertension associated with a known predisposing disease were at lower hazard of death in comparison to cats that were diagnosed with hypertension after presentation for clinical signs.
This finding was most likely because of hypertension being diagnosed earlier in cats being monitored for it, and therefore decreasing the risk of TOD in these cats. It is also possible that this association with survival is caused by lead time bias, because cats diagnosed while being monitored for a pre-existing disease are diagnosed earlier and they are considered to have had hypertension longer than they would have had if they were not diagnosed until clinical signs of hypertension were present. Cats that received investigations for an underlying cause of their hypertension also had a lower hazard of death in comparison to those cats that did not. This is likely associated with the owners being more proactive in treatment of hypertension in their cats, and these cats may have had increased monitoring after diagnosis of hypertension and therefore better treatment. A dose change in amlodipine was associated with decreased hazard of death. Cats that had a dose change of amlodipine had significantly more blood pressure measurements after diagnosis of hypertension in comparison to cats that did not receive a dose change. It seems most likely that the association between dose change and survival was related to improved monitoring after diagnosis and better treatment, because these cats had blood pressure measurements after diagnosis to identify the lack of response to amlodipine at the initial dose. It is also possible that owners who are more committed to monitoring and treatment of hypertension in their cats are more likely to have uncontrolled hypertension identified and that improved survival associated with dose change is an indirect effect of this vigilance. Proteinuria was not found to be associated with survival, unlike findings in previous studies. 8 This difference is likely because of the small numbers of cats that had UPC measured, leading to the study being underpowered to detect this association.
A subgroup analysis was undertaken to see if there were any associations between blood pressure at diagnosis and treatments received and between treatments received and average blood pressure after diagnosis. These analyses were performed primarily for hypothesis-generating purposes. Cats receiving amlodipine treatment had higher blood pressure at diagnosis than did cats receiving benazepril. This observation may be caused by veterinarians being unwilling to prescribe amlodipine to cats they perceived to have mild hypertension "on the cascade" (a UK system for deciding what medicine should be used for a condition in a particular species 30 ) because, at the time this study was conducted, amlodipine did not have a product authorization for cats. 30 The preparations of amlodipine available for human in 2012-2015 required tablets to be divided into much smaller doses for cats. It also may be that veterinarians were concerned about potential adverse effects of amlodipine, although it has been shown recently that amlodipine has no more adverse effects than a placebo. 15 These considerations may explain why some veterinarians opted to give benazepril to cats with less severe hypertension. No controlling for confounding was performed in this subgroup analysis, and unrecognized confounding may be present.
Our study had a number of limitations. It is possible that potential cases were not identified from the searches because of veterinarians using different terms in the EPR. This limitation was shown to be of low significance by a pilot study carried out to informally assess the sensitivity and specificity of the search terms. The case definition relied on veterinarians performing a BPA and correctly identifying hypertension, no minimum blood pressure was required. Also, it was not possible to validate the techniques used by clinicians, the interpre- practice. By identifying hypertension early, we may be able to decrease associated morbidity and improve survival, thus improving the health and welfare of cats diagnosed with hypertension in the UK.
